- Home
- WNW vs VIVS Comparison
WNW vs VIVS Comparison
Compare WNW & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WNW
- VIVS
- Stock Information
- Founded
- WNW 2015
- VIVS 2007
- Country
- WNW China
- VIVS United States
- Employees
- WNW N/A
- VIVS N/A
- Industry
- WNW Catalog/Specialty Distribution
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WNW Consumer Discretionary
- VIVS Health Care
- Exchange
- WNW Nasdaq
- VIVS Nasdaq
- Market Cap
- WNW 5.7M
- VIVS 4.6M
- IPO Year
- WNW 2020
- VIVS N/A
- Fundamental
- Price
- WNW $1.69
- VIVS $1.77
- Analyst Decision
- WNW
- VIVS
- Analyst Count
- WNW 0
- VIVS 0
- Target Price
- WNW N/A
- VIVS N/A
- AVG Volume (30 Days)
- WNW 15.8K
- VIVS 53.7K
- Earning Date
- WNW 08-26-2025
- VIVS 08-12-2025
- Dividend Yield
- WNW N/A
- VIVS N/A
- EPS Growth
- WNW N/A
- VIVS N/A
- EPS
- WNW 9.06
- VIVS N/A
- Revenue
- WNW $158,485.00
- VIVS $142,000.00
- Revenue This Year
- WNW N/A
- VIVS $42.38
- Revenue Next Year
- WNW N/A
- VIVS $15.42
- P/E Ratio
- WNW $0.19
- VIVS N/A
- Revenue Growth
- WNW N/A
- VIVS 94.52
- 52 Week Low
- WNW $0.95
- VIVS $1.41
- 52 Week High
- WNW $70.00
- VIVS $21.96
- Technical
- Relative Strength Index (RSI)
- WNW 40.81
- VIVS N/A
- Support Level
- WNW $1.66
- VIVS N/A
- Resistance Level
- WNW $1.82
- VIVS N/A
- Average True Range (ATR)
- WNW 0.09
- VIVS 0.00
- MACD
- WNW -0.01
- VIVS 0.00
- Stochastic Oscillator
- WNW 18.73
- VIVS 0.00
About WNW Meiwu Technology Company Limited
Meiwu Technology Co Ltd operates as an online food retail store and franchise restaurants in China. The products offered include green food, organic food, intangible cultural heritage food products, agricultural products bearing geographical indications, and pollution-free products. It operates in three segments including Clean Food platform, Skincare products & service and Technical Service. The company generates the majority of its revenue from Technical services.
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.